Cushing's syndrome is caused by prolonged exposure to elevated levels of either endogenous or exogenous glucocorticoids. The degree of cortisol overproduction is very variable. When presentation is florid, diagnosis is usually straightforward. However, the presentation may be subtle and the combination of nonspecific clinical manifestations and variable cyclical biochemical parameters often makes the diagnosis difficult. Because of the significant morbidity and mortality of Cushing's syndrome, early diagnosis and prompt treatment are essential.
Causes of Cushing's syndrome can be divided into two groups:
- Adrenocorticotropic hormone (ACTH)-dependent disease: excessive ACTH from the pituitary (Cushing's disease), ectopic ACTH-producing tumours or excess ACTH administration.
- Non-ACTH-dependent: adrenal adenomas, adrenal carcinomas, excess glucocorticoid administration.
- Incidence of Cushing's syndrome is in the region of 10 to 15 people per million, with a higher incidence in people with diabetes, obesity, hypertension or osteoporosis.
- In obese patients with type 2 diabetes, especially those with poor blood glucose control and hypertension, the reported prevalence of Cushing's syndrome is between 2% and 5%.
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
- Cushing's syndrome due to an adrenal or pituitary tumour is more common in females (ratio 5:1).
- The peak incidence of Cushing's syndrome caused by an adrenal or pituitary adenoma is between the ages of 25 and 40 years.
- Ectopic ACTH production due to lung cancer occurs later in life.
The most common cause of Cushing's syndrome is the use of exogenous glucocorticoids. Endogenous Cushing's syndrome is divided into corticotropin-dependent and corticotropin-independent causes:
- Corticotropin-dependent causes account for about 80-85% of cases:
- 80% are due to pituitary adenomas (Cushing's disease).
- The remaining 20% are due to ectopic corticotropin syndrome, which is usually due to small-cell carcinoma of the lung and bronchial carcinoid tumours, but may occur with almost any endocrine tumour, eg phaeochromocytoma, pancreatic neuroendocrine tumours, medullary thyroid cancer, gut carcinoids.
- Corticotropin-independent Cushing's syndrome:
- Truncal obesity, supraclavicular fat pads, buffalo hump, weight gain.
- Facial fullness, moon facies, facial plethora.
- Proximal muscle wasting and weakness.
- Diabetes or impaired glucose tolerance.
- Gonadal dysfunction, reduced libido.
- Skin: skin atrophy, purple striae, easy bruising, hirsutism, acne; pigmentation occurs with ACTH-dependent causes.
- Psychological problems: depression, cognitive dysfunction and emotional lability.
- Osteopenia or osteoporosis.
- Women may complain of irregular menses.
- Thirst, polydipsia, polyuria.
- Impaired immune function: increased infections, difficulty with wound healing.
- Child: growth restriction.
- Patients with an ACTH-producing pituitary tumour may develop headaches, visual problems, and galactorrhoea.
- Destruction of the anterior pituitary may cause hypothyroidism and amenorrhoea.
Pseudo-Cushing's syndrome: all or some of the clinical features of Cushing's syndrome, combined with biochemical evidence of hypercortisolism (but not caused by pituitary-adrenal axis problems). Causes include:
- Chronic severe anxiety and/or depression.
- Prolonged excess alcohol consumption, which can cause a Cushingoid appearance.
- Poorly controlled diabetes.
- HIV infection.
No single test is perfect and several different tests are usually needed.
- Investigations are usually carried out following referral; it is often easier to co-ordinate the investigations in secondary care and ensure earlier diagnosis and effective management.
- Investigations should be performed when there is no acute concurrent illness (eg infection or heart failure), as these can cause false-positive results.
Investigations to confirm the presence of Cushing's syndrome
The recommended diagnostic tests for the presence of Cushing's syndrome are 24-hour urinary free cortisol, 1 mg overnight dexamethasone suppression test, and late-night salivary cortisol.
- FBC: raised white cell count.
- Electrolytes and acid-base balance: hypokalaemia (common with ectopic ACTH secretion as a result of mineralocorticoid activity), metabolic alkalosis.
- 24-hour urinary free cortisol:
- Ideally three collections. Measure creatinine excretion at the same time.
- Cushing's syndrome can be confidently diagnosed if two or more collections measure cortisol excretion as more than three times the laboratory upper limit of normal.
- Need to repeat the test if creatinine excretion varies by more than 10% between collections.
- False positives may occur with pregnancy, anorexia, exercise, psychoses, alcohol and alcohol withdrawal. Strenuous exercise and illness raise cortisol secretion.
- Low-dose dexamethasone suppression test:
- A useful screening test in those who are unable to reliably collect a 24-hour urine sample.
- 1 mg of dexamethasone is ingested at 11 pm, and serum cortisol is measured at 8 am the next morning.
- Mild Cushing's syndrome is often difficult to distinguish from normal cortisol secretion or pseudo-Cushing's syndrome, and both false-positive and false-negative test results occur.
- Midnight cortisol levels:
- Taken between 11 pm and 1 am. Demonstrate loss of normal diurnal variation of reduced cortisol production in the evening compared to the morning.
- Need to take blood from an indwelling cannula with the patient in a relaxed state.
- Inconvenient but reliable test for Cushing's syndrome.
- Late-night salivary cortisol measurement is a simple and reliable screening test for Cushing's syndrome.
- Dexamethasone suppressed corticotropin-releasing hormone (CRH) test:
- Modification of the low-dose dexamethasone suppression test.
- IV CRH is given 2 hours after 48 hours (eight doses) of 0.5 mg dexamethasone. Serum cortisol is measured 15 minutes after ovine CRH administration.
- Very reliable test for Cushing's syndrome.
Investigations to identify the cause of Cushing's syndrome
- Plasma ACTH:
- Secretion is pulsatile and shows a diurnal variation, with the plasma concentrations highest at 8 am and lowest at midnight. The secretion of ACTH is increased by stress.
- An undetectable plasma ACTH with an elevated serum cortisol level is diagnostic of ACTH-independent Cushing's syndrome, which is due to a primary cortisol-producing adrenal adenoma or carcinoma, or exogenous glucocorticoid use. This should then be followed by an abdominal CT or MRI scan if exogenous glucocorticoids are excluded as the cause.
- An elevated ACTH level is consistent with ACTH-dependent Cushing's syndrome.
- If the plasma ACTH level is detectable then the following tests are indicated:
- High-dose dexamethasone suppression test:
- The 8 mg overnight dexamethasone suppression test and the 48-hour high-dose dexamethasone test may be useful when baseline ACTH levels are equivocal. They also help in determining whether a patient has pituitary or ectopic ACTH production.
- Greater than 90% reduction in basal urinary free cortisol levels supports the diagnosis of a pituitary adenoma; ectopic ACTH causes lesser degrees of suppression.
- Inferior petrosal sinus sampling (IPS):
- Performed with CRH stimulation to aid in determining the source of excess ACTH.
- A baseline and stimulated ratio of IPS to peripheral ACTH of less than 1.8 is suggestive of ectopic ACTH, while a ratio of IPS to peripheral ACTH of greater than 2 is consistent with a pituitary adenoma.
- MRI of the pituitary.
- Chest and abdominal CT scans: for patients with suspected adrenal tumours or ectopic ACTH.
- Plasma CRH: ectopic CRH production is a very rare cause of Cushing's syndrome.
Definitive therapy of endogenous Cushing's syndrome involves tumour resection. Indications for medical therapy include acutely ill patients in preparation for surgery, patients with unknown tumour location or unresectable lesions, patients unfit for surgery and patients with persistent raised glucocorticoid levels postoperatively.
- The treatment of choice in most patients is surgical but the metabolic consequences, including increased tissue fragility, poor wound healing, hypertension, and diabetes mellitus, increase the risks of surgery.
- Drug therapy remains very important for normalising cortisol levels while awaiting the impact of more definitive treatment.
- Cortisol hypersecretion must be controlled prior to surgery or radiotherapy if at all possible.
- Metyrapone, ketoconazole, and mitotane can all be used to lower cortisol by directly inhibiting synthesis and secretion in the adrenal gland.
- Metyrapone and ketoconazole are enzyme inhibitors and have rapid onset of action, but control of hypercortisolism is often lost with corticotropin oversecretion in Cushing's disease. These drugs are not usually effective as long-term treatment and are used mainly for preparation for surgery or as adjunctive treatment after surgery or pituitary radiotherapy.
- Mitotane acts as an adrenolytic drug with delayed onset but long-lasting action, but control of corticotropin oversecretion in Cushing's disease is maintained.
- Medical treatment can also be used in patients who are unwilling or unfit for surgery. Treatment can be used long-term for patients with ectopic corticotropin secretion, but adrenalectomy may be preferred.
- Etomidate can be used for acute control of severe hypercortisolaemia.
Is the treatment of choice for the following conditions:
- Pituitary tumours: trans-sphenoidal microsurgery. Radiation therapy may be used as an adjunct for patients who are not cured. Bilateral adrenalectomy may be necessary to control toxic cortisol levels.
- Adrenocortical tumours: require surgical removal. Laparoscopic surgery is now the treatment of choice for unilateral adrenal adenomas.
- Removal of neoplastic tissue is indicated for ectopic ACTH production. Metastatic spread makes a surgical cure unlikely or impossible. Bilateral adrenalectomy is indicated if necessary to control toxic cortisol levels.
- Persisting hypercortisolaemia after trans-sphenoidal surgery can be treated with pituitary radiotherapy.
- Conventional fractionated radiotherapy is very effective but is associated with long-term hypopituitarism and can be very delayed in effectiveness.
Patients with Cushing's syndrome often develop:
- Metabolic syndrome.
- Impaired glucose tolerance and diabetes.
- Hyperlipidaemia: raised LDL cholesterol and triglycerides.
- Coagulopathy: thrombophilia.
- Perforated viscera.
- Impaired immunity, including opportunistic fungal infections.
- Nelson's syndrome, which may follow bilateral adrenalectomy for Cushing's disease.
- A primary pituitary tumour, which may cause panhypopituitarism and visual loss.
- Patients with incompletely controlled Cushing's syndrome have a five-fold excess mortality.
- The causes of premature death in untreated Cushing's syndrome are vascular disease (myocardial infarction/stroke), uncontrolled diabetes mellitus and complications of diabetes, and infections.
- The usual course is chronic, with cyclic exacerbations and rare remissions.
- The prognosis is guardedly favorable with surgery.
- The rare adrenocortical carcinomas have a 5-year survival rate of 30% or less.
Further reading & references
- Newell-Price J, Bertagna X, Grossman AB, et al; Cushing's syndrome. Lancet. 2006 May 13;367(9522):1605-17.
- Arnaldi G, Angeli A, Atkinson AB, et al; Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602.
- Biller BM, Grossman AB, Stewart PM, et al; Treatment of ACTH-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008 Apr 15;.
- Guaraldi F, Salvatori R; Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med. 2012 Mar;25(2):199-208.
- Adler GK, Cushing Syndrome, Medscape, Feb 2012
- Boscaro M, Arnaldi G; Approach to the patient with possible Cushing's syndrome. J Clin Endocrinol Metab. 2009 Sep;94(9):3121-31.
- Tritos NA, Biller BM; Advances in medical therapies for Cushing's syndrome. Discov Med. 2012 Feb;13(69):171-9.
- Morris D, Grossman A; The medical management of Cushing's syndrome. Ann N Y Acad Sci. 2002 Sep;970:119-33.
- Shalet S, Mukherjee A; Pharmacological treatment of hypercortisolism. Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):234-8.
- Tritos NA, Biller BM, Swearingen B; Management of Cushing disease. Nat Rev Endocrinol. 2011 May;7(5):279-89. Epub 2011 Feb 8.
- Becker G, Kocher M, Kortmann RD, et al; Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol. 2002 Apr;178(4):173-86.
- Clayton RN; Mortality in Cushing's disease. Neuroendocrinology. 2010;92 Suppl 1:71-6. Epub 2010 Sep 10.
|Original Author: Dr Colin Tidy||Current Version: Dr Colin Tidy||Peer Reviewer: Dr Adrian Bonsall|
|Last Checked: 14/08/2012||Document ID: 2024 Version: 22||© EMIS|
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.